This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frohlich, E. D. Search for Related Content PubMed PubMed Citation Articles by Frohlich, E. D.

REVIEW ARTICLES

The necessity for recognition and treatment of patients with "mild" hypertension¹

^* Alton Ochsner Medical Foundation, New Orleans, Louisiana, USA

Manuscript received June 10, 1999; revised manuscript received June 23, 1999, accepted June 30, 1999.

Reprint requests and correspondence: Dr. Edward D. Frohlich, Alton Ochsner Medical Foundation, 1516 Jefferson Highway, New Orleans, Louisiana 70124

A dramatic evolution has occurred in the past four decades in our underlying knowledge of pathophysiology of the hypertensive diseases and in the availability of myriad pharmacologic agents for control of hypertension. This report provides a current review of antihypertensive treatment interspersed with personal opinions supported by appropriate references. It focuses on the recent national recommendations dealing with the prevention, detection, evaluation and treatment of the disease (JNC-6). Whereas I believe that the height of arterial pressure is of primary importance, it is not the sine qua non explaining all target organ involvement or complications of hypertensive disease. Consequently, all that is classified today as Stages 1 and 2 hypertension (old terminology: "mild" and "moderate") in terms of blood pressure elevation does not explain all outcomes of disease. Indeed, JNC-6 introduced the new concept of risk stratification for therapy based not only on the height of systolic and diastolic pressure but also on the presence of target organ involvement, comorbidity and other risk factors. However, after considerable advances since the inception of the National High Blood Pressure Education Program (NHBPEP) in 1972, it appears that we are avoiding our responsibilities and reversing our gains. It is of vital importance that we renew our efforts to identify, evaluate and treat all patients with hypertension; this is especially so for the vast numbers of patients with Stages 1 and 2 hypertension.

Abbreviations and Acronyms   ACE = angiotensin converting enzyme   ARB = angiotensin II (type I) receptor blocker   CHD = coronary heart disease   ESRD = end stage renal disease   JNC-5 and JNC-6 = national recommendations dealing with the prevention, detection, evaluation and treatment of hypertensive disease   MI = myocardial infarction   NHBPEP = National High Blood Pressure Education Program

This article has been cited by other articles:

				H. M. Perry, E. D. Freis, and E. D. Frohlich Department of Veterans Affairs Hypertension Meeting : A Proposal for Improved Care Hypertension, April 1, 2000; 35(4): 853 - 857. [Abstract] [Full Text] [PDF]